HCV - Valeant buys InterMune hepatitis C drug

Valeant buys InterMune hepatitis C drug
bizjournals.com via Yahoo! Finance - Jan 03 8:35 AM
Valeant Pharmaceuticals International said Tuesday it closed its purchase of the United States and Canadian rights to hepatitis C drug Infergen from InterMune Inc. for $113.5 million in cash.Save to My Web

Vertex Drug Shows Promise in Hepatitis C
RedNova - 49 minutes ago
New data from a phase Ib study show that Vertex Pharmaceutical's VX-950 dosed in combination with pegylated interferon alfa-2a, achieved a rapid and dramatic reduction in virus levels in genotype 1 patients with chronic hepatitis C infection.Save to My Web

GlobeImmune raises $38M
bizjournals.com via Yahoo! Finance - 1 hour, 48 minutes ago
Biotech company GlobeImmune has raised $38 million through a round of Series B financing, the company said Tuesday.Save to My Web

Human Genome Sciences Announces Decision to Spin Off CoGenesys Division as an Independent Company
[Press Release] PR Newswire via Yahoo! Finance - Dec 13 1:05 PM
Human Genome Sciences, Inc. today announced that it has decided to spin off its CoGenesys division as an independent company that will focus on the early development of selected gene-based product opportunities and the monetization of certain Human Genome Sciences intellectual property and technology assets.Save to My Web

Viral Hepatitis Conference to Take Place February 27-28, 2006 in Boston, MA
RedNova - Jan 05 8:20 AM
BOSTON, Jan. 5 /PRNewswire/ -- Chronic hepatitis C (HCV) and B (HBV) are the most common causes of chronic viral hepatitis in the United States, posing serious risks for long-term medical complications, especially if left untreated.Save to My Web